Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | COVID-19 | Research

Impact of the COVID-19 outbreak and interventions on hand, foot and mouth disease in Zhengzhou, China, 2014–2022: a retrospective study

Authors: Wanyu Jia, Xue Zhang, Ruiyang Sun, Peng Li, Chunlan Song

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

Since December 2019, COVID-19 has spread rapidly around the world, and studies have shown that measures to prevent COVID-19 can largely reduce the spread of other infectious diseases. This study explored the impact of the COVID-19 outbreak and interventions on the incidence of HFMD.

Methods

We gathered data on the prevalence of HFMD from the Children’s Hospital Affiliated to Zhengzhou University. An autoregressive integrated moving average model was constructed using HFMD incidence data from 2014 to 2019, the number of cases predicted from 2020 to 2022 was predicted, and the predicted values were compared with the actual measurements.

Results

From January 2014 to October 2022, the Children’s Hospital of Zhengzhou University admitted 103,995 children with HFMD. The average number of cases of HFMD from 2020 to 2022 was 4,946, a significant decrease from 14,859 cases from 2014 to 2019. We confirmed the best ARIMA (2,0,0) (1,1,0)12 model. From 2020 to 2022, the yearly number of cases decreased by 46.58%, 75.54%, and 66.16%, respectively, compared with the forecasted incidence. Trends in incidence across sexes and ages displayed patterns similar to those overall.

Conclusions

The COVID-19 outbreak and interventions reduced the incidence of HFMD compared to that before the outbreak. Strengthening public health interventions remains a priority in the prevention of HFMD.
Literature
1.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199–207.CrossRefPubMedPubMedCentral
2.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRefPubMedPubMedCentral
3.
Mallah SI, Ghorab OK, Al-Salmi S, Abdellatif OS, Tharmaratnam T, Iskandar MA, et al. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 2021;20(1):35.CrossRefPubMedPubMedCentral
4.
Tian H, Liu Y, Li Y, Wu CH, Chen B, Kraemer MUG, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science. 2020;368(6491):638–42.CrossRefPubMedPubMedCentral
5.
Sun J, Shi Z, Xu H. Non-pharmaceutical interventions used for COVID-19 had a major impact on reducing influenza in China in 2020. J Travel Med. 2020;27(8).
6.
Feng L, Zhang T, Wang Q, Xie Y, Peng Z, Zheng J, et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat Commun. 2021;12(1):3249.CrossRefPubMedPubMedCentral
7.
Chen B, Wang M, Huang X, Xie M, Pan L, Liu H, et al. Changes in incidence of notifiable infectious diseases in China under the Prevention and Control measures of COVID-19. Front Public Health. 2021;9:728768.CrossRefPubMedPubMedCentral
8.
Huang QM, Song WQ, Liang F, Ye BL, Li ZH, Zhang XR, et al. Non-pharmaceutical interventions implemented to Control the COVID-19 were Associated with reduction of Influenza Incidence. Front Public Health. 2022;10:773271.CrossRefPubMedPubMedCentral
9.
Zhao X, Li M, Haihambo N, Jin J, Zeng Y, Qiu J, et al. Changes in temporal properties of notifiable infectious disease epidemics in China during the COVID-19 pandemic: Population-based Surveillance Study. JMIR Public Health Surveill. 2022;8(6):e35343.CrossRefPubMedPubMedCentral
10.
China NHCoPsRo. Diagnosis and treatment guideline on hand, foot and mouth disease(2018. Chin J Clin Infect Dis. 2018;11(3):161–6.
11.
Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37(3):391–8.CrossRefPubMed
12.
Li XW, Ni X, Qian SY, Wang Q, Jiang RM, Xu WB, et al. Chinese guidelines for the diagnosis and treatment of hand, foot and mouth disease (2018 edition). World J Pediatr. 2018;14(5):437–47.CrossRefPubMed
13.
Li CH, Mao JJ, Wu YJ, Zhang B, Zhuang X, Qin G, et al. Combined impacts of environmental and socioeconomic covariates on HFMD risk in China: a spatiotemporal heterogeneous perspective. PLoS Negl Trop Dis. 2023;17(5):e0011286.CrossRefPubMedPubMedCentral
14.
Huang X, Wei H, Wu S, Du Y, Liu L, Su J, et al. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Henan, China, 2008–2013. Sci Rep. 2015;5:8904.CrossRefPubMedPubMedCentral
15.
Schaffer AL, Dobbins TA, Pearson S-A. Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions. BMC Med Res Methodol. 2021;21(1):58.CrossRefPubMedPubMedCentral
16.
Benvenuto D, Giovanetti M, Vassallo L, Angeletti S, Ciccozzi M. Application of the ARIMA model on the COVID-2019 epidemic dataset. Data Brief. 2020;29:105340.CrossRefPubMedPubMedCentral
17.
Jayaraj VJ, Hoe VCW. Forecasting HFMD cases using Weather variables and Google Search queries in Sabah, Malaysia. Int J Environ Res Public Health. 2022;19(24).
18.
Geng MJ, Zhang HY, Yu LJ, Lv CL, Wang T, Che TL, et al. Changes in notifiable infectious disease incidence in China during the COVID-19 pandemic. Nat Commun. 2021;12(1):6923.CrossRefPubMedPubMedCentral
19.
Adegbija O, Walker J, Smoll N, Khan A, Graham J, Khandaker G. Notifiable diseases after implementation of COVID-19 public health prevention measures in Central Queensland, Australia. Commun Dis Intell (2018). 2021;45.
20.
Hibiya K, Iwata H, Kinjo T, Shinzato A, Tateyama M, Ueda S, et al. Incidence of common infectious diseases in Japan during the COVID-19 pandemic. PLoS ONE. 2022;17(1):e0261332.CrossRefPubMedPubMedCentral
21.
Huang QS, Wood T, Jelley L, Jennings T, Jefferies S, Daniells K, et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nat Commun. 2021;12(1):1001.CrossRefPubMedPubMedCentral
22.
Shen L, Sun M, Song S, Hu Q, Wang N, Ou G, et al. The impact of anti-COVID-19 nonpharmaceutical interventions on hand, foot, and mouth disease-A spatiotemporal perspective in Xi’an, northwestern China. J Med Virol. 2022;94(7):3121–32.CrossRefPubMedPubMedCentral
23.
Wang XF, Lu J, Liu XX, Dai T. Epidemiological Features of Hand, Foot and Mouth Disease outbreaks among Chinese Preschool children: a Meta-analysis. Iran J Public Health. 2018;47(9):1234–43.PubMedPubMedCentral
24.
Laor P, Apidechkul T, Khunthason S, Keawdounglek V, Sudsandee S, Fakkaew K, et al. Association of environmental factors and high HFMD occurrence in northern Thailand. BMC Public Health. 2020;20(1):1829.CrossRefPubMedPubMedCentral
25.
26.
Mao Q, Wang Y, Bian L, Xu M, Liang Z. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5(7):e75.PubMedPubMedCentral
27.
Wang J, Jiang L, Zhang C, He W, Tan Y, Ning C. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine. Vaccine. 2021;39(25):3319–23.CrossRefPubMed
28.
Ruan F, Yang T, Ma H, Jin Y, Song S, Fontaine RE, et al. Risk factors for hand, foot, and mouth disease and herpangina and the preventive effect of hand-washing. Pediatrics. 2011;127(4):e898–904.CrossRefPubMed
29.
Guo N, Ma H, Deng J, Ma Y, Huang L, Guo R, et al. Effect of hand washing and personal hygiene on hand food mouth disease: a community intervention study. Med (Baltim). 2018;97(51):e13144.CrossRef
30.
Fu T, Chen T, Dong ZB, Luo SY, Miao Z, Song XP, et al. Development and comparison of forecast models of hand-foot-mouth disease with meteorological factors. Sci Rep. 2019;9(1):15691.CrossRefPubMedPubMedCentral
Metadata
Title
Impact of the COVID-19 outbreak and interventions on hand, foot and mouth disease in Zhengzhou, China, 2014–2022: a retrospective study
Authors
Wanyu Jia
Xue Zhang
Ruiyang Sun
Peng Li
Chunlan Song
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
COVID-19
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09244-w

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue

Research

A cross-sectional study of SARS-CoV-2 antibodies among healthcare workers in a tertiary care hospital in Taiwan: implications for protection against the Omicron variants

Case Report

Unexpected severe malaria in a postoperative patient, New York, USA

Research

Collateral effects of COVID-19 countermeasures on hepatitis E incidence pattern: a case study of china based on time series models

Research

Modelling respiratory syncytial virus age-specific risk of hospitalisation in term and preterm infants

Research

Predicting the incidence of infectious diarrhea with symptom surveillance data using a stacking-based ensembled model

Research

Correlation between a low serum free triiodothyronine level and mortality of severe pulmonary tuberculosis patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits